International Journal of Scientific Research in Science and Technology
Available online at : www.ijsrst.com
OPEN ACCESS
Print ISSN: 2395-6011 | Online ISSN: 2395-602X
doi : https://doi.org/10.32628/IJSRST251268

Advanced Biologics and Smart Delivery Systems for Cardiovascular Diseases: A Comprehensive Review

Paras Ghasura[1], Bhavika Murlidhar Sajnani[1], Mohammad Azhar Tanveer[2], Barath Raj R[3], Dr Abhishek Sharma[4]

[1]A-One Pharmacy College, Ahmedabad, Gujarat, India

[2]Rajiv Memorial Education Society's College of Pharmacy, Gulbarga, Karnataka, India

[3]C L Baid Metha College of Pharmacy, Tamil Nadu, India

[4]Hakeem Abdul Hameed Centenary Hospital (HAHC Hospital), India

ARTICLEINFO

Article History:

Accepted : 01 July 2025
Published: 11 July 2025

Publication Issue :
Volume 12, Issue 4
July-August-2025

Page Number :
217-221

ABSTRACT

Background: Cardiovascular diseases (CVDs) remain the leading global cause of mortality, accounting for 20.5 million deaths annually. Traditional pharmacotherapies face limitations including poor bioavailability and systemic toxicity.

Objective: To review the integration of advanced biological therapeutics with innovative drug delivery platforms for cardiovascular applications.

Methods: Systematic analysis of 127 peer-reviewed articles from PubMed, Scopus, and Web of Science databases (2020-2025), focusing on FDA-approved biologics and emerging delivery technologies.

Results: PCSK9 inhibitors demonstrate 50-60% LDL cholesterol reduction with significant cardiovascular event reduction. Advanced delivery systems including nanoparticles, stimuli-responsive carriers, and extracellular vesicles enhance therapeutic precision while minimizing adverse effects. Clinical successes include inclisiran achieving sustained efficacy with biannual dosing.

Conclusion: The integration of biologics with smart delivery systems represents a paradigm shift toward personalized cardiovascular medicine with significant potential to improve patient outcomes.

Keywords: Cardiovascular diseases, biologics, nano medicine, drug delivery systems, PCSK9 inhibitors, targeted therapy

I. INTRODUCTION

Cardiovascular diseases constitute the most significant global health challenge, accounting for 20.5 million deaths in 2021 and representing one-third of all global mortality[1]. Traditional small-molecule cardiovascular drugs present inherent limitations including narrow therapeutic windows, significant off-target effects, and suboptimal bioavailability[2].

The emergence of biological therapeutics such as monoclonal antibodies, nucleic acid-based medicines, and cellular therapies that offers unprecedented specificity. However, biologics face challenges related to stability, immunogenicity, and targeted delivery[3]. Smart delivery systems, including Nano particulate carriers and stimuli-responsive platforms, enable precise spatiotemporal control while minimizing systemic toxicity[4].

This review examines the current landscape of cardiovascular biologics, evaluates cutting-edge delivery technologies, and analyzes their clinical translation potential based on analysis of 127 peer-reviewed publications.

II. BIOLOGICS IN CARDIOVASCULAR THERAPY

2.1 Monoclonal Antibodies

PCSK9 Inhibitors: PCSK9 inhibitors have revolutionized cholesterol management. Evolocumab and alirocumab demonstrate 50-60% LDL cholesterol reduction with 15% reduction in major adverse cardiovascular events[5–7].

Drug	Mechanism	Primary Outcome	Efficacy	FDA Approval
Evolocumab	Anti-PCSK9 mAb	LDL-C reduction	60%	2015
Alirocumab	Anti-PCSK9 mAb	LDL-C reduction	58%	2015
Inclisiran	siRNA vs PCSK9	LDL-C reduction	52%	2021
Canakinumab	Anti-IL-1β	MACE reduction	15%	2017

Table 1: Clinical Efficacy of Approved Cardiovascular Biologics

Anti-Inflammatory Agents: Canakinumab targeting IL-1β demonstrated the inflammation hypothesis in the CANTOS trial, achieving 15% MACE reduction[8]. However, infection risk and cost have limited adoption.

2.2 RNA-Based Therapeutics

Small Interfering RNA: Inclisiran represents the first FDA-approved siRNA for cardiovascular disease, utilizing GalNAc conjugation for hepatic targeting and achieving sustained PCSK9 reduction with biannual dosing[9].

Messenger RNA Therapeutics: Following COVID-19 vaccine success, mRNA platforms are investigated for myocardial regeneration using VEGF and growth factors[10].

2.3 Gene and Cell Therapies: Gene therapy approaches target fundamental cardiovascular pathophysiology, with alipogene tiparvovec approved for familial lipoprotein lipase deficiency[11]. Current investigations focus on genetic cardiomyopathies and myocardial regeneration.

III.ADVANCED DRUG DELIVERY PLATFORMS

3.1 Nanoparticle-Based Systems

Lipid Nanoparticles (LNPs): LNPs serve as the gold standard for nucleic acid delivery, comprising ionizable lipids, PEG-lipids, cholesterol, and phospholipids. Clinical success includes COVID-19 mRNA vaccines and inclisiran delivery[12].

Polymeric Nanoparticles: PLGA and biodegradable polymers offer controlled release (days to months), excellent biocompatibility, and surface functionalization capabilities[13].

Platform	Size (nm)	Advantages	Clinical Status	Applications
LNPs	50-200	High RNA loading	Approved	siRNA delivery
PLGA	100-500	Sustained release	Phase II/III	Protein drugs
Liposomes	50-400	Biocompatible	Approved	Chemotherapy

Platform	Size (nm)	Advantages	Clinical Status	Applications
Dendrimers	1-10	Multivalent	Phase I/II	Imaging agents

Table 2: Nanoparticle Platforms for Cardiovascular Applications

3.2 Stimuli-Responsive Systems

These carriers release drugs responding to internal (pH, enzymes) or external (ultrasound, magnetic fields) stimuli[14].

pH-Responsive Systems; Exploit acidic microenvironments in atherosclerotic plaques (pH 6.5-7.0) and ischemic myocardium (pH 6.0-6.8)[15].

Ultrasound-Triggered Systems: Micro bubble-mediated sonoporation enables targeted drug delivery to atherosclerotic plaques[16].

3.3 Extracellular Vesicles

EVs offer natural biocompatibility, intrinsic targeting, and cargo versatility. Multiple Phase I/II trials are investigating EV-based cardiovascular therapies[17].

IV. TARGETING STRATEGIES

4.1 Passive Targeting: Enhanced permeability and retention (EPR) effect enables nanoparticle accumulation in atherosclerotic plaques, infarcted myocardium, and angiogenic vessels[18].

4.2 Active Targeting

Target	Ligand	Expression Site	Clinical Status
αvβ3 integrin	RGD peptide	Angiogenic vessels	Phase II
ICAM-1	Anti-ICAM-1	Activated endothelium	Phase I
VCAM-1	Anti-VCAM-1	Atherosclerotic plaques	Preclinical
P-selecting	PSGL-1 mimetic	Activated platelets	Preclinical

Table 3: Active Targeting Approaches

V. ALTERNATIVE DELIVERY ROUTES

5.1 Transdermal and Micro needle Systems: Traditional transdermal patches are established for nitroglycerin and clonidine. Micro needle technology enables painless delivery of biologics with dissolving, hollow, and coated variants under development[19].

5.2 Injectable Hydrogels: Injectable hydrogels provide sustained release (weeks to months) through in situ gelation, supporting cardiac repair applications[20].

5.3 Implantable Devices: Cardiac pumps for continuous inotrope infusion and drug-eluting stents for local antiproliferative delivery represent established technologies[21].

VI. CLINICAL TRANSLATION AND REGULATORY LANDSCAPE

6.1 FDA-Approved Systems: Current approved systems include inclisiran (siRNA), PCSK9 monoclonal antibodies (evolocumab, alirocumab), and liposomal doxorubicin (Doxil®) for reduced cardiotoxicity[22–24].

6.2 Clinical Pipeline

Phase III Trials:

- Olezarsen (antisense oligonucleotide) for hypertriglyceridemia
- Pelacarsen (antisense vs Lp(a)) for cardiovascular outcomes
- Zilebesiran (siRNA vs angiotensinogen) for hypertension[25]

6.3 Regulatory Considerations: Key requirements include physicochemical characterization, biological assessment, stability studies, and

manufacturing consistency. FDA breakthrough designations have accelerated development of 23 cardiovascular biologics (2020-2025)[26].

VII. CHALLENGES AND FUTURE DIRECTIONS

7.1 Current Challenges

Technical Barriers:

- Cold chain requirements and formulation stability
- Manufacturing scalability and quality control
- Immunogenicity and off-target effects[27]

Economic Barriers:

- High development costs ($1-3B per approved drug)
- Limited reimbursement and patient access
- Geographic disparities in healthcare infrastructure[28]

7.2 Future Opportunities

Artificial Intelligence Integration: AI applications include target identification, formulation design, and personalized medicine approaches[29].

Next-Generation Technologies

- DNA origami and protein cage delivery systems
- Synthetic biology approaches
- Advanced targeting with aptamers and bispecific antibodies[30]

Market Projections: The global cardiovascular drug delivery market projects 8.2% CAGR (2024-2030), driven by aging populations and technological advancement[31].

VIII. CONCLUSIONS

The integration of biologics with smart delivery systems represents a transformative approach to cardiovascular medicine. PCSK9 inhibitors and RNA therapeutics demonstrate superior efficacy compared to traditional therapies, while advanced delivery platforms successfully address biological barriers. Clinical translation has achieved significant milestones with multiple FDA-approved products.

Key recommendations include: (1) prioritizing translational research addressing clinical delivery challenges, (2) embracing interdisciplinary collaboration, (3) developing platform technologies for multiple cardiovascular indications, and (4) addressing manufacturing scalability early in development.

The successful convergence of biologics with innovative delivery systems holds unprecedented promise for revolutionizing cardiovascular care and significantly impacting global disease burden.

Funding

The authors declare that no funding was received for this work.

Conflicts of Interest

The authors declare no conflicts of interest.

REFERENCES

[1]. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2024 Update. Circulation. 2024;149(8):e347-e913.

[2]. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals. Nat Rev Drug Discov. 2014;13(9):655-672.

[3]. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265-280.

[4]. Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124.

[5]. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.

[6]. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107.

[7]. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia. J Am Coll Cardiol. 2014;63(23):2531-2540.

[8]. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.

[9]. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519.

[10]. Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31(10):898-907.

[11]. Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec in patients with lipoprotein lipase deficiency. Gene Ther. 2019;26(6):256-265.

[12]. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094.

[13]. Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.

[14]. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.

[15]. Zhang Y, Yu J, Bomba HN, et al. Mechanical force-triggered drug delivery. Chem Rev. 2016;116(19):12536-12563.

[16]. Chen H, Zhang W, Zhu G, et al. Rethinking cancer nanotheranostics. Nat Rev Mater. 2017;2(7):17024.

[17]. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

[18]. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J Control Release. 2000;65(1-2):271-284.

[19]. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.

[20]. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):16071.

[21]. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321-1331.

[22]. Leqvio® (Inclisiran) Prescribing Information. Novartis. 2021.

[23]. Repatha® (Evolocumab) Prescribing Information. Amgen. 2015.

[24]. Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.

[25]. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255.

[26]. FDA Breakthrough Therapy Designation Database. 2024. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals

[27]. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65(1):104-120.

[28]. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33.

[29]. Chen R, Liu X, Jin S, et al. Machine learning for drug-target interaction prediction. Molecules. 2018;23(9):2208.

[30]. Seeman NC. DNA nanotechnology. Nat Rev Mater. 2018;3(1):17068.

[31]. Global Cardiovascular Drug Delivery Market Report 2024. Research and Markets. 2024.